Abstract:Abstract Childhood cancer survivors are at increased risk of subsequent neoplasms (SN), largely considered to be therapy-related. Studies of cancer predisposition genes (CPGs) and risk of SN among long-term survivors are lacking. We characterized germline mutations in CPGs in childhood cancer survivors to determine their contribution to SN risk. Whole genome (30x) and exome (100x) sequencing was performed for 2988 5+ year survivors of childhood cancer (1629 leukemia/lymphoma, 332 CNS, 1027 other solid tumors, 53% male, median follow-up 28 [range 6-55] years). Survivors underwent a comprehensive clinical assessment, treatment exposures were abstracted from medical records, and SN were validated by pathology reports. Germline mutations in 63 CPGs were classified using the American College of Medical Genetics and Genomics guidelines as previously described (Zhang et al. NEJM 2015). Logistic regression, adjusting for age, sex and race, was used to evaluate associations between mutation status, cancer therapy and the SN risk. 1062 SNs were diagnosed in 437 survivors, of whom 98 developed ≥2 histologically distinct SNs. Median age at SN and time to first SN was 38.2 (range 3.3-67.4) and 29.2 (0.9-48.4) years, respectively. Common SNs were basal cell carcinoma (542 in 153 survivors), meningioma (201 in 100), thyroid (64 in 64), and breast cancer (58 in 50). Cumulative incidence of SN at age 45 was 25.5% (95% CI: 22.9-27.9). 169 survivors (5.7%) had a pathogenic/likely pathogenic (P/LP) mutation in a CPG, consisting of 97 single nucleotide variations, 63 insertion/deletions and 9 copy number alterations (49% of mutations not in ClinVar). Frequently mutated genes were: RB1 (n=41), NF1 (n=22), BRCA2 (n=13), BRCA1 (n=12) and TP53 (n=10). Our data confirmed known associations between CPG mutations and specific primary diagnoses including RB1 mutations in 32 of 41 (78%) of bilateral and 7 of 57 (12%) of unilateral retinoblastoma survivors, 22 NF1 (20 of 332 CNS survivors), 4 SUFU (all in medulloblastoma survivors) and 5 WT1 mutations (all in Wilms’ tumor survivors). Analyses revealed novel associations between CPG mutations and SN risk. Among 1326 survivors not exposed to radiation therapy (non-RT), 62 SNs developed in 54 survivors, of which 15 (24.2%) occurred in P/LP mutation carriers. Non-RT exposed survivors with a P/LP mutation had an increased risk of SN (OR=5.6, 95% CI=2.6-12.0, P<0.001) and the odds of developing ≥2 distinct histologic types of SNs was increased by 23.6-fold (95% CI=5.4-102.7, P<0.001). In 1662 RT exposed survivors, P/LP-mutation carriers had an odds ratio of 2.3 (95% CI=0.9-6.0, P=0.08) for developing ≥2 distinct histologic types of SNs. Our findings indicate that a substantial proportion of non-RT exposed childhood cancer survivors who develop one or more SN carry a CPG mutation, and should be referred to genetic testing and counseling services. Citation Format: Zhaoming Wang, Carmen L. Wilson, John Easton, Dale Hedges, Qi Liu, Gang Wu, Michael Rusch, Michael Edmonson, Shawn Levy, Jennifer Q. Lanctot, Eric Caron, Kyla Shelton, Kelsey Currie, Matthew Lear, Heather L. Mulder, Donald Yergeau, Celeste Rosencrance, Bhavin Vadodaria, Yadav Sapkota, Russell J. Brooke, Wonjong Moon, Evadnie Rampersaud, Xiaotu Ma, Shuoguo Wang, Ti-Cheng Chang, Stephen Rice, Andrew Thrasher, Aman Patel, Cynthia Pepper, Xin Zhou, Xiang Chen, Wenan Chen, Angela Jones, Braden Boone, Deo Kumar Srivastava, Chimene A. Kesserwan, Kim E. Nichols, James R. Downing, Melissa M. Hudson, Yutaka Yasui, Leslie L. Robison, Jinghui Zhang. Germline mutations in cancer predisposition genes and risk for subsequent neoplasms among long-term survivors of childhood cancer in the St. Jude Lifetime Cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3001. doi:10.1158/1538-7445.AM2017-3001

Multiple Subsequent Neoplasms in the Childhood Cancer Survivor Study (ccss) Cohort

Genetic Risk for Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer.

Long-Term Risk of Subsequent Neoplasms in 5-Year Survivors of Childhood Neuroblastoma: A Dutch Childhood Cancer Survivor Study-LATER 3 Study

Increased risk of subsequent neoplasm after hematopoietic stem cell transplantation in 5-year survivors of childhood acute lymphoblastic leukemia

Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report

Abstract 3001: Germline Mutations in Cancer Predisposition Genes and Risk for Subsequent Neoplasms among Long-Term Survivors of Childhood Cancer in the St. Jude Lifetime Cohort

Abstract 6155: Germline variants in cancer susceptibility genes and subsequent neoplasm risks after childhood cancer: A pooled analysis of two large-scale cohorts

Risk of Second Primary Cancers among Long-Term Survivors of Breast Cancer

Second malignant neoplasms in childhood malignant brain tumour: a long-term population-based study.

Genetic risk of second malignant neoplasm after childhood cancer treatment: A systematic review

Pathogenic Germline Mutations in DNA Repair Genes in Combination with Cancer Treatment Exposures and Risk of Subsequent Neoplasms among Long-Term Survivors of Childhood Cancer

Impact of Risk-Based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the childhood cancer survivor study

Cancer Germline Predisposing Variants and Late Mortality from Subsequent Malignant Neoplasms among Long-Term Childhood Cancer Survivors: a Report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study.

Risk of Second Malignant Neoplasms among Long-Term Survivors of Early Stage Extranodal Nasal-Type Natural Killer/t-Cell Lymphoma

Genome-Wide Association Study in Irradiated Childhood Cancer Survivors Identifies HTR2A for Subsequent Basal Cell Carcinoma.

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report

Polygenic Risk Of Subsequent Thyroid Cancer After Childhood Cancer: A Report From St. Jude Lifetime Cohort (Sjlife) And Childhood Cancer Survivor Study (Ccss).

Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry

Polygenic risk scores, radiation treatment exposures and subsequent cancer risk in childhood cancer survivors

Abstract 3007: Monogenic and Polygenic Associations with Subsequent Breast Cancer Risk in Survivors of Childhood Cancer: the St. Jude Lifetime Cohort Study (SJLIFE)

Prevalence of pathogenic variants in cancer-predisposing genes in second cancer after childhood solid cancers